INTRODUCTION
The gastrointestinal drug market is growing rapidly due to recent advancements in pharmaceutical products, advancements in drug delivery of medications and accurate diagnoses. Although the pharmaceutical industry as a whole has several potential blockbuster drugs in late-stage development, productivity has been lower than expected, particularly in light of higher outlays for research and development. It is troubling for the pharmaceutical industry that new drugs are coming to market in the U.S. at the slowest rate in a decade. This comes despite a three-fold increase in research spending (to $30 billion) and a major overhaul of the U.S. Food and Drug Administration's (FDA) approval process.
Biotechnology products have had a significant impact on overall patient morbidity and mortality. There are several products on the market to treat various gastrointestinal disorders and diseases and many more in clinical trials. These prescription products are expected to greatly impact the market by pushing revenues higher and fueling demands for innovative treatments for gastrointestinal disorders.
This BCC study analyzes therapeutics currently on the market as well as potential products and classes of products that likely will have a significant impact on the future of both the prescription gastrointestinal drug and the over-the-counter gastrointestinal drug markets.
SCOPE OF STUDY
The report contains:
METHODOLOGY AND INFORMATION SOURCES
The information and analysis presented in this BCC report are based on extensive first hand interviews with primary executives, product managers, and clinical specialists in the gastrointestinal pharmaceutical arena. Background information was obtained from various government agencies, and medical journals, trade magazines, and interviews with doctors and nurses involved in the treatment of gastrointestinal disorders.
Key information from published literature was used to conduct interviews with over 45 industry participants to validate and obtain expert opinions on current and future trends in the gastrointestinal pharmaceutical industry. Interviews were the primary basis for development of market size. Interviews were also used to confirm and/or adjust market size and market share estimates, as well as formulating market projections.
All market data pertain to the U.S. market at the manufacturer's level. Data are expressed in current U.S. dollars. The base year was 2004. Historical data are provided for 2002 and 2003 and forecast data are provided for 2009. Historical, base year and forecast data are provided for each market segment and subsegment. Market shares are provided for each market segment for the 2004 base year.
ANALYST CREDENTIALS
Mary Anne Crandall has been publishing market research in the life sciences for more than 17 years. She holds a Master of Science Degree in psychology, and is the founder and CEO of Mountaintop Medical, LLC, a consulting firm in Oregon. She has taught at Southern Oregon University for more than 16 years, and before joining BCC's analytical team, she published with Frost & Sullivan, Theta Reports, FIND/SVP, MDI, FeedBack Research Services, Prognosis and Hall Enterprises. Ms. Crandall specializes in prescription pharmaceutical markets.
